Double-blind, parallel-group confirmatory study of AD-810N (zonisamide) in patients with Parkinson's disease

INTERVENTION: Intervention name : AD‐810N (zonisamide) Dosage And administration of the intervention : oral CONDITION: Parkinson's disease PRIMARY OUTCOME: Unified Parkinson's Disease Rating Scale (UPDRS) INCLUSION CRITERIA: [Major inclusion criteria] ‐ Patients with reduced response to L‐DOPA ‐ Age: >=20 and <75 (at the time of informed consent) [Major exclusion criteria] ‐ Patients with Parkinson's syndrome other than Parkinson's disease ‐ Patients with epilepsy ‐ Patients with a history of treatment with zonisamide, or who have ever enrolled in other clinical trials related to AD‐810N ‐ Patients with a history of neuroleptic malignant syndrome